Affordable Access

Discontinuation of secondary prophylaxis for cryptococcal meningitis in human immunodeficiency virus-infected patients treated with highly active antiretroviral therapy: a prospective, multicenter, randomized study.

Authors
Type
Published Article
Journal
Clinical Infectious Diseases
1537-6591
Publisher
Oxford University Press
Publication Date
Volume
36
Issue
10
Pages
1329–1331
Identifiers
PMID: 12746781
Source
Medline
License
Unknown

Abstract

A prospective, multicenter, randomized study was conducted with human immunodeficiency virus (HIV)-infected patients who were successfully treated for acute cryptococcal meningitis, were receiving secondary prophylaxis, and were naive for antiretroviral therapy. Patients were randomized to continue or discontinue secondary prophylaxis when the CD4 cell count had increased to >100 cells/microL and an undetectable HIV RNA level had been sustained for 3 months. At a median of 48 weeks after randomization, there were no episodes of cryptococcal meningitis in either group.

Statistics

Seen <100 times